title: Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.
abstract: BACKGROUND
  This study was conducted to determine the efficacy and safety of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for patients with desmoid tumors refractory to meloxicam treatment, focusing in particular on the relationship between the efficacy of this chemotherapy and catenin β-1 (CTNNB1) mutation status.
  
  
  METHODS
  Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week. The responses of all patients were evaluated, and factors that were correlated with efficacy were analyzed, including CTNNB1 mutation status.
  
  
  RESULTS
  Sixty-eight patients were prospectively treated with meloxicam. MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression. A few patients showed grade 3-4 treatment-related toxicity with the administration of MTX and VBL every other week. Intriguingly, CTNNB1 status did not affect the efficacy of this treatment.
  
  
  CONCLUSIONS
  MTX and VBL treatment every other week is well tolerated and achieved a favorable response in patients resistant to meloxicam treatment, regardless of CTNNB1 mutation status.
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan. ynishida@med.nagoya-u.ac.jp.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishida
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tsukushi
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.|Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, 466-8550, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Urakawa
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Hamada
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
authors.forename: Eiji
authors.initials: E
authors.lastname: Kozawa
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Ikuta
authors.affiliation: Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, 466-8550, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ando
authors.affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishiguro
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D018221:Fibromatosis, Abdominal / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D008297:Male; D000077239:Meloxicam; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009154:Mutation; D019233:Retreatment; D013843:Thiazines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D014747:Vinblastine / Q000008:administration & dosage; D055815:Young Adult; D051176:beta Catenin / Q000235:genetics*
chemical_list: C495270:CTNNB1 protein, human; D052246:Cyclooxygenase 2 Inhibitors; D013843:Thiazines; D013844:Thiazoles; D051176:beta Catenin; D014747:Vinblastine; D000077239:Meloxicam; D008727:Methotrexate
keywords: CTNNB1; Desmoid tumor; Methotrexate; Vinblastine